Onconetix Major Shareholder Increases Stake

Financial Lp Hrt buys additional 74,350 shares of the biotech company

Apr. 17, 2026 at 11:04am

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate gears and components of a high-tech medical device, representing the complex financial infrastructure supporting Onconetix's biotech innovations.The heavy, industrial machinery behind Onconetix's biotech advancements signals the institutional backing and financial resources fueling the company's growth.Cincinnati Today

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt acquired 74,350 additional shares of the company's stock in a transaction on Tuesday, April 14th. The shares were purchased at an average cost of $0.77 per share, for a total transaction of $57,249.50. Following the acquisition, Financial Lp Hrt now owns 104,498 shares in Onconetix, valued at approximately $80,463.46.

Why it matters

This insider buying activity by a major shareholder suggests confidence in Onconetix's future prospects. As a biotech company focused on men's health and oncology solutions, Onconetix's performance is closely watched by investors seeking exposure to the growing healthcare sector.

The details

In the transaction, Financial Lp Hrt increased its ownership stake in Onconetix by 246.62%. The firm now holds over 104,000 shares, or about 0.84% of the company's total outstanding stock. Onconetix's share price has fluctuated significantly over the past year, trading between $0.67 and $74.29.

  • On Tuesday, April 14th, 2026, Financial Lp Hrt bought 74,350 shares of Onconetix stock.
  • On Wednesday, April 15th, 2026, Financial Lp Hrt bought an additional 92,554 shares of Onconetix stock.

The players

Financial Lp Hrt

A major shareholder of Onconetix, Inc. that has increased its ownership stake in the company through recent stock purchases.

Onconetix, Inc.

A biotechnology company focused on developing solutions for men's health and oncology, including FDA-approved products like Entadfi and Proclarix.

Got photos? Submit your photos here. ›

What’s next

Investors will likely continue to monitor Onconetix's stock performance and any further insider trading activity as the company progresses with its product pipeline and commercialization efforts.

The takeaway

This insider buying by a major shareholder signals confidence in Onconetix's long-term growth potential within the expanding men's health and oncology markets. The company's recent FDA approvals and pipeline developments make it an interesting biotech play for investors seeking exposure to innovative healthcare solutions.